All articles by Elly Earls

How India’s use of unapproved antibiotics could undermine global health

Millions of unapproved antibiotics are being sold in India, some by multinationals, according to a new study by researchers at…
Could focusing on the user experience reinvent drug R&D software?

Well-designed software created with the user experience (UX) in mind has the potential to vastly improve the efficiency and productivity…
Could a new antibody screening method lead to better drugs?

Antibody proteins have been the fastest-growing class of approved drugs over the last two decades, but current antibody drug discovery…
Where are the pharma manufacturing hotspots?

Pharmaceutical manufacturing is a profitable business – whether it’s the production of active pharmaceutical ingredients (APIs) or finished pharmaceutical products…
Seamless trials: the key to more drug approvals?

As pressure increases on the pharmaceutical industry and its regulators to speed up the drug development and approvals process without…

Block and lock: a functional cure for HIV?

Existing HIV therapies are extremely effective at reducing the amount of virus in the blood and tissue of patients. But…
Slipper limpet slime: a biotech treasure chest?

Currently busy degrading water quality and causing havoc among native oyster fisheries in European oceans, the invasive gastropod species the…
Dundee University: visiting the world’s most influential pharmaceutical research institution

Clarivate Analytics has named Dundee University the world’s most influential pharmaceuticals research institution in its State of Innovation report, which…
From biologics to biosimilars: NHS move makes big sense

The NHS plans to slash £300m from its annual pharmaceuticals bill by using biosimilar medicines – cheaper but equally clinically…
Could treating heart diseases with anti-inflammatories be the biggest breakthrough since statins?

A research team in the US has found that anti-inflammatory drugs could reduce the risk of heart attacks, independent of…